2847775-85-1
2847775-85-1
Chemical Structure
Oleoylcarnitine-d9
- CAS No.: 2847775-85-1
- Formula:C25H38D9NO4
- Molecular Weight:434.70
InChIKey: IPOLTUVFXFHAHI-LUTOIHIRSA-N
SMILES: CCCCCCCC/C=C\CCCCCCCC(O[C@H](CC([O-])=O)C[N+](C([2H])([2H])[2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])=O
Biological Activity: Oleoylcarnitine-d9 is deuterium labeled Oleoylcarnitine. Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation[1][1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Oleoylcarnitine-d9 | 99.0% | Oleoylcarnitine-d9 is deuterium labeled Oleoylcarnitine. Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oleoylcarnitine (Standard) | ≥98% | Oleoylcarnitine (Standard) is the analytical standard of Oleoylcarnitine. This product is intended for research and analytical applications. Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oleoylcarnitine-13C,d3 | Oleoylcarnitine-13C,d3 is the deuterium and 13C-labeled Oleoylcarnitine (HY-113261). Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Oleoylcarnitine | 99.95% | Oleoylcarnitine, the metabolite which accumulates through suppression of fatty acid β-oxidation, can enhance hepatocarcinogenesis via STAT3 activation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Fujiwara N, et al. CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. Gut. 2018 Aug;67(8):1493-1504. [Content Brief]
